As previously reported, H.C. Wainwright analyst Debjit Chattopadhyay raised his price target on Global Blood Therapeutics shares to $125 from $73, telling investors that after the company unveiled the HOPE Part A data the voxelator investment thesis is "no longer relying on just hope." The early data hit his "homerun situation" on the primary endpoint, with a dose-dependent and statistically-significant increase in hemoglobin, Chattopadhyay stated. Bears are likely to argue about whether the data are sufficient to convince the FDA to grant an early approval, but that "pales in comparison" to the actual clinical benefit, added the analyst, who raised his peak global sales estimate for voxelator to about $2.3B from a prior view of $1.6B. He maintains a Buy rating on Global Blood shares.